Accutane Once-Daily Version Should Have Three-Year Phase-In - FDA Cmte.

Roche should take three years to replace the current formulation of Accutane (isotretinoin) with a once-daily version, FDA Dermatologic & Ophthalmic Drugs Advisory Committee voting consultant Lloyd King, MD/PhD, said during the panel's Sept. 19 meeting.